enzymes and other proteins involved in the adenosine axis (e.g., A2bR) revealed trends that could have predictive value, particularly in late-line subjects. Correlative trends were also observed between the infiltration of lymphocytes within baseline tumor samples and the extent of clinical benefit. Based on a preliminary and ongoing analysis of baseline biopsies, a number of molecular markers may correlate with better clinical outcomes, most relevantly in late-line mCRC subjects treated with AB928 + mFOLFOX-6. These data suggest the possibility that adenosine-related markers may be helpful in future studies for selection of patients to be treated with AB928 + mFOLFOX-6 therapy.

Conclusions N/A

Acknowledgements N/A

Trial Registration NCT03720678

Ethics Approval The study was approved by all the study site Institution’s Ethics Boards, with Advarra IRB being the first, approval number SSU00070639 in USA.

Consent N/A

REFERENCES

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0338

Abstracts

PRELIMINARY SAFETY, TOLERABILITY AND EFFICACY RESULTS OF KN026 (A HER2-TARGETED BISPECIFIC ANTIBODY) IN COMBINATION WITH KN046 (AN ANTI-PD-L1/CTLA-4 BISPECIFIC ANTIBODY) IN PATIENTS (PTS) WITH HER2 AMBERLATED SOLID TUMORS

1Jifang Geng*, 2Jie Dong, 3Dan Liu, 4Jingan Lu, 1Jing Yang, 2Yakun Qi, 1Tanya Dorff, 2Matthew Rettig, 3Jean-Pascal Machiels, 4Martijn Lolkema, 4Karen Autio, 5Lihua Zhu, 1Jifang Geng*, 1Zhi Dong, 1Dan Liu, 2June Xu, 1Ting Xu, 1Lin Shen. 1Beijing Cancer Hospital, Beijing, China; 2Tianjin Medical University Cancer Institute, Tianjin, People’s Republic of China; 3Cliniques Universitaires Saint-Luc, Brussels, Belgium; 4Erasmus MC Cancer Institute, Rotterdam, Netherlands; 5Memorial Sloan Kettering Cancer Center, New York, NY, United States; 6City of Hope, Duarte, CA, United States

Background HER2 potently inhibits innate immunity through cGAS–STING signalling,1 meanwhile HER2 antibody induced ADCP will also lead to macrophage mediated immune suppression. Preclinical and clinical studies suggested a coordination of engagement of innate and adaptive immunity with the combination of an anti-HER2 antibody and an immune checkpoint blockade. KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86. Here we reported the interim results from an ongoing phase Ib dose escalation and expansion study assessing the safety, tolerability and preliminary efficacy for KN026 in combination with KN046.

Methods This study enrolled pts with solid tumors who failed available standard of care, HER2 aberration status confirmed locally (HER2 mutation, HER2 amplification and/or HER2 overexpression). Eligible pts received combination of KN026 and KN046 at two dose levels until disease progression, unacceptable toxicity or withdrawal of informed consent (DL1: KN026 20 mg/kg Q2W + KN046 3 mg/kg Q2W; DL2: KN026 20 mg/kg Q2W with loading on Days 1, 8 of Cycle 1 + KN046 5 mg/kg Q3W). Tumor response was evaluated Q8W per RECIST 1.1. Primary endpoint was DLT and key secondary endpoints were efficacy parameters (ORR, DOR, PFS).

Results As of the Jul. 13, 2020, 21 pts were enrolled into DL1 (n = 18, 3 for dose escalation) and DL2 (n = 3) (mGC/GEJ 12 pts; mCRC 7 pts; other solid tumors 2 pts). 11 pts remained on the study treatment and 10 pts discontinued treatment due to disease progression (n=5), death (n=2) and other reasons (n=3). 15 pts had HER2-positive status (11 of 15 failed previous trastuzumab therapy), 1 pt had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). No DLTs were observed. No pts experienced LVEF decreased or other clinically meaningful cardiac AEs. Treatment-related TEAEs occurred in 13 pts, of which 1 pt experienced grade 3 or above treatment-related TEAEs. 7 pts experienced irAEs, all of which were grade 1 or 2. The most common (≥10%) KN026 or KN046 related TEAEs were anaemia (n=5, 23.8%), AST increased (n=4, 19.0%), rash (n=4, 19.0%), diarrhea (n=4, 19.0%), blood bilirubin increased (n=3, 14.3%) and infusion related reaction (n=3, 14.3%). The objective response rate in pts with HER2-positive tumors (n = 7 efficacy evaluable pts) was 4/7 (57.1%, 95% CI 18.4–90.1%) and disease control rate 6/7 (85.7%, 95% CI 42.1–99.6%). 3 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks. 2 death cases only received one cycle of KN026 plus KN046 due to COVID-19 restriction before died from clinical deterioration from underlying tumors.

Conclusions KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors.

Trial Registration NCT04040699

Ethics Approval The study was approved by Beijing Cancer Hospital Institution’s Ethics Board, approval number 2019YJZ37.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

REFERENCES

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0339

PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE® (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

1Tanya Dorff, 2Matthew Rettig, 3Jean-Pascal Machiels, 4Karen Auto, 5Richard Greil, 2Sylvie Rottey, 4Nabil Adra, 5Mark Salwati, 6Shelley Poon, 1Daniel Tan, 5Gabor Jurida, 2Hosein Kouros-Mehr, 1Tanya Dorff, 2Matthew Rettig, 3Jean-Pascal Machiels, 4Martijn Lolkema, 4Karen Autio. 1City of Hope, Duarte, CA, United States; 2UCLA, Los Angeles, CA, United States; 3Cliniques Universitaires Saint-Luc, Brussels, Belgium; 4Erasmus MC Cancer Institute, Rotterdam, Netherlands; 5Memorial Sloan Kettering Cancer Center, New York, NY, United States; 6Illicit Medical Department, Paracelsus Med, Salzburg, Austria; 2Drug Research Unit Ghent, Ghent, Belgium; 3Indiana University School of Medicine, Indianapolis, IN, United States; 4Angen Inc, Thousand Oaks, CA, United States; 5National Cancer Centre Singapore, Singapore, Singapore; 6University of Paris Sud, Villejuif, France; 7Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 8Chris O’Brien Lifehouse, Campbelltown, Australia

Background Prostate-specific membrane antigen (PSMA) is a clinically validated target for metastatic castration-resistant prostate cancer (mCRPC). AMG 160 BiTE® immuno-oncology therapy redirects T cells to cancer cells by binding to
Background BXCL701 (talabostat) is an oral small molecule inhibitor of dipeptidyl peptidases (DPP) primarily DPP8 and DPP9, which triggers inflammasome mediated pyroptosis in macrophages leading to induction of IL-18 and IL-1beta, bridging between innate and adaptive immunity. PD-L1 expression correlates with amplification of DPP8 and DPP9. In syngeneic animal models, significant tumor growth inhibition was observed with BXCL701 plus checkpoint inhibition. In a prior clinical study, single-agent BXCL701 resulted in objective responses in patients (pts) with Stage IV melanoma (unpublished).

Methods In Phase 1b portion of this multicenter study, eligible pts had progressing mCRPC (PCWG3), ≥1 prior systemic therapy, ≤2 lines of cytotoxic chemotherapy for mCRPC, no prior anti-PD-1/PD-L1 or other T-cell directed immunotherapy, ≥1 prior line of cytotoxic chemotherapy (n = 11), RT (n = 11). On-target AEs consistent with cytokine activation were seen at the highest dose levels. In the 0.6 mg qd cohort, all pts had events consistent with cytokine release: 3/3 had hypotension (including 1 grade 3 syncope (DLT)) and 2 pts each had dizziness and LE edema. Splitting the 0.6 mg dose improved the tolerability while maintaining the TDD previously associated with objective response; 3/7 pts had fatigue, and 1 pt each had low grade hypotension, dyspnea, chills, myalgia. Preliminary anti-tumor activity was seen with 1 pt achieving a PSA response and 3 pts with RECIST1.1 stable disease. BXCL701 was quantifiable in plasma. Consistent dose and time dependent increases in serum IL-18 levels were observed with 0.6 mg split dose.

Conclusions BXCL701 0.3 mg BID (0.6 mg TDD) administered on days 1–14 was identified as the RP2D when administered with pembrolizumab 200 mg every 21 days. Splitting the TDD was associated with improved tolerability as evidenced by no reported DLTs and lower rates of other adverse events of interest such as hypotension and peripheral edema. The Phase 2 portion of the study is enrolling.

Acknowledgements All patients, their families, and caregivers who make this study possible; the participating investigators...